IOL

The Synchrony dual-optic accommodative intraocular lens (Abbott Medical Optics) seems to be clinically safe and effective after 2 years of follow-up. The visual function at intermediate and far improved rapidly postoperatively. Half of patients require a +1 D prescription for near vision.

When consulting with patients who present with decreased vision due to cataracts, ophthalmologists need to remember their role as physicians first, suggest the authors. The primary goal of the office visit is to address the complaint and the solution in entirety before moving into outcomes.

Among the 2013 ASCRS clinical survey results on astigmatism, findings showed that 57% of physicians saw benefits associated with femtosecond laser arcuate incisions compared with conventional manual incisions. Other trends were identified from the more than 1,000 physician responses.

Early treatment of pediatric cataracts is crucial, with proper consideration being given to age and the type of postoperative correction to be used.

A dual-optic accommodating IOL (Synchrony, Abbott Medical Optics) seems to have met the presbyopic challenge by providing good vision at far and intermediate distances.

An array of IOLs under development and in clinical trials show promise for correcting presbyopia or addressing other limitations of existing pseudophakic lenses.

Bausch + Lomb have announced the U.S. introduction of BLIS (Bausch + Lomb Injector System), designed exclusively for use with the enVista glistening-free, hydrophobic acrylic IOL.

Numerous reports show that phacoemulsification lowers IOP, but further research is needed to understand what mediates the change, according to Douglas J. Rhee, MD.

A patient satisfaction and quality-of-life survey found that three presbyopia-correcting IOLs provide better spectacle independence than monovision.

The majority of cataract patients likely have significant tear film disturbances that can affect their preoperative measurements and postoperative satisfaction with cataract surgery.

Kevin Lavery, MD, describes his technique for implanting a 1-piece acrylic astigmatic lens (Tecnis Toric IOL, Abbott Medical Optics) through a 2.2-mm incision or even smaller.

Omeros Corp. has announced that it recently submitted a new drug application to the FDA for approval of a new drug for use in patients undergoing IOL replacement (ILR) surgery.

A light-adjustable IOL continues to show potential for delivering customized vision with predictable results.

A single-piece hydrophobic acrylic IOL has many features that make it a good choice for a monofocal implant in routine and challenging cataract surgery cases.

Secondary IOL implantation is widely accepted, especially in aphakic patients who have become contact lens intolerant or noncompliant. A number of studies on the topic, mostly from Western countries, have had small sample sizes, and the safety and efficacy of the procedure have not been well studied.

The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of cataract patients with pre-existing corneal astigmatism.

It is not always easy to fit the right IOL to the right patient to correct presbyopia. It is not that approved lenses do not work as expected, according to Richard Chu, DO, medical director, Chu Eye Associates, Fort Worth, TX, but that each lens has slightly different optical characteristics. Not every lens is right for every patient.

New clinical data suggest that an improved intraoperative aberrometer can help improve clinical outcomes for patients who receive an aspheric, hydrophobic IOL, said Dee Stephenson, MD, of Stephenson Eye Associates in Venice, FL.

Ophthalmology has a history of “strange,” and actually that may be good for the specialty. Of all the specialties of medicine, ophthalmology keeps seeing innovation evolve on a regular basis. The technology in this market is always evolving and it keeps getting better and more efficient.

Upgrade may make traditional manual lens delivery a thing of the past

Results from quality of life and vision surveys provide insight on patient-based subjective outcomes after bilateral implantation of presbyopia-correcting IOLs.